BIO Tells Congress How to Maintain US Biotech Leadership

Why It Matters

Strengthening biotech policy safeguards America’s health security and fuels a high‑value export industry, keeping the U.S. competitive in a market projected to exceed $4 trillion.

Key Takeaways

• Global biotech market projected $4.25T by 2033.
• BIO urges federal R&D tax credit expansion.
• Proposes Angel Investor Tax Credit for biotech startups.
• Calls for incentives to reshape U.S. contract manufacturing.
• Suggests national biomanufacturing strategy office for coordination.

Pulse Analysis

The biotechnology sector has become a cornerstone of U.S. economic competitiveness, with analysts forecasting a $4.25 trillion global market by 2033. This growth is driven by breakthroughs in gene therapy, mRNA vaccines, and personalized medicine, all of which rely on sustained federal support. Policy mechanisms such as R&D tax credits and targeted investment incentives are critical for maintaining the pipeline of innovation that fuels both domestic health outcomes and export revenues.

BIO’s recommendations focus on creating a more attractive financing environment for emerging biotech firms. A federal Angel Investor Tax Credit would encourage high‑net‑worth individuals to fund early‑stage companies, while expanded R&D credits would lower the cost of discovery. Parallel incentives for contract manufacturing—ranging from tax breaks to grant‑backed capital—aim to reshoring critical production capabilities, reducing reliance on overseas facilities and strengthening supply chain resilience. Workforce development programs tied to regional biomanufacturing hubs would also address the talent gap, ensuring a pipeline of skilled engineers and technicians.

Beyond domestic policy, BIO stresses the importance of coordinated trade and oversight strategies. Bilateral agreements that eliminate tariffs on biopharmaceuticals and reinforce intellectual property protections could open new markets for U.S. products. An interagency task force or dedicated National Biomanufacturing Strategy Office would streamline regulatory actions, aligning federal resources with industry needs. Together, these measures promise to protect national security, accelerate scientific breakthroughs, and sustain the United States’ position as the world’s leading biotech innovator.